IL-6 impairs myogenic differentiation by downmodulation of p90RSK/eEF2 and mTOR/p70S6K axes, without affecting AKT activity

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Pelosi, Michele ^a   De Rossi, Manuela ^a   Barberi, Laura ^a   Musarò, Antonio ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; P70 RIBOSOMAL S6 KINASE; P90 RIBOSOMAL S6 KINASE; S6 KINASE; STAT3 PROTEIN; TRANSCRIPTION FACTOR E2F2; UNCLASSIFIED DRUG; INITIATION FACTOR 2; MTOR PROTEIN, MOUSE; PROTEIN KINASE B; RIBOSOMAL PROTEIN S6 KINASE, 90KDA, POLYPEPTIDE 3; STAT3 PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ADENOCARCINOMA; ANIMAL CELL; ARTICLE; CACHEXIA; CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HOMEOSTASIS; MODULATION; MOLECULAR MECHANICS; MOUSE; MUSCLE DEVELOPMENT; MYOGENIC DIFFERENTIATION; NONHUMAN; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; EUKARYOTIC INITIATION FACTOR-2; INTERLEUKIN-6; MICE; MUSCLE DEVELOPMENT; MUSCLE FIBERS, SKELETAL; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES;

EID: 84902198074     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/206026     Document Type: Article

References (33)

1. Clegg C. H., Linkhart T. A., Olwin B. B., Hauschka S. D., Growth factor control of skeletal muscle differentiation: commitment to terminal differentiation occurs in G1 phase and is repressed by fibroblast growth factor. Journal of Cell Biology 1987 105 2 949 956 2-s2.0-0023606959 (Pubitemid 18043854)
2. Olson N. E., Sternberg E., Hu J. S., Spizz G., Wilcox C., Regulation of myogenic differentiation by type β transforming growth factor. Journal of Cell Biology 1986 103 5 1799 1805 2-s2.0-0022977185 (Pubitemid 17189035)
3. Musarò A., Rosenthal N., Maturation of the myogenic program is induced by postmitotic expression of insulin-like growth factor I. Molecular and Cellular Biology 1999 19 4 3115 3124 2-s2.0-0032949353 (Pubitemid 29144556)
4. Musarò A., McCullagh K. J. A., Naya F. J., Olson E. N., Rosenthal N., IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 1999 400 6744 581 585 2-s2.0-0033526991 10.1038/23060 (Pubitemid 29381809)
5. Strassmann G., Fong M., Kenney J. S., Jacob C. O., Evidence for the involvement of interleukin 6 in experimental cancer cachexia. The Journal of Clinical Investigation 1992 89 5 1681 1684 2-s2.0-0026689535
6. Miller S. C., Ito H., Blau H. M., Torti F. M., Tumor necrosis factor inhibits human myogenesis in vitro. Molecular and Cellular Biology 1988 8 6 2295 2301 2-s2.0-0023924058
7. Coletti D., Yang E., Marazzi G., Sassoon D., TNF α inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. EMBO Journal 2002 21 4 631 642 2-s2.0-0037083867 10.1093/emboj/21.4. 631 (Pubitemid 34174044)
8. Guttridge D. C., Mayo M. W., Madrid L. V., Wang C.-Y., Baldwin A.S. J., NF- B-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000 289 5488 2363 2365 2-s2.0-0034730251 10.1126/science.289. 5488.2363
9. Muñoz-Cánoves P., Scheele C., Pedersen B. K., Serrano A. L., Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? FEBS Journal 2013 280 17 4131 4148 10.1111/febs.12338
10. Pedersen B. K., Febbraio M. A., Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiological Reviews 2008 88 4 1379 1406 2-s2.0-55949119252 10.1152/physrev.90100.2007
11. Baeza-Raja B., Muñoz-Cánoves P., p38 MAPK-induced nuclear factor-kappaB activity is required for skeletal muscle differentiation: role of interleukin-6. Molecular Biology of the Cell 2004 15 4 2013 2026 2-s2.0-1642423481 10.1091/mbc.E03-08-0585 (Pubitemid 38401847)
12. Hoene M., Runge H., Häring H. U., Schleicher E. D., Weigert C., Interleukin-6 promotes myogenic differentiation of mouse skeletal muscle cells: role of the STAT3 pathway. American Journal of Physiology. Cell Physiology 2013 304 2 C128 C136 2-s2.0-84875580640 10.1152/ajpcell.00025.2012
13. Serrano A. L., Baeza-Raja B., Perdiguero E., Jardí M., Muñoz-Cánoves P., Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metabolism 2008 7 1 33 44 2-s2.0-37449022587 10.1016/j.cmet.2007.11.011
14. De Benedetti F., Meazza C., Martini A., Role of interleukin-6 in growth failure: an animal model. Hormone Research 2002 58 supplement 1 24 27 2-s2.0-0036422745 (Pubitemid 35316833)
15. Franckhauser S., Elias I., Rotter Sopasakis V., Ferré T., Nagaev I., Andersson C. X., Agudo J., Ruberte J., Bosch F., Smith U., Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia 2008 51 7 1306 1316 2-s2.0-44749084540 10.1007/s00125-008- 0998-8
16. Haddad F., Zaldivar F., Cooper D. M., Adams G. R., IL-6-induced skeletal muscle atrophy. Journal of Applied Physiology 2005 98 3 911 917 2-s2.0-14144252542 10.1152/japplphysiol.01026.2004 (Pubitemid 40283672)
17. Perry R. L., Rudnick M. A., Molecular mechanisms regulating myogenic determination and differentiation. Frontiers of Bioscience 2000 1 5 D750 D767 2-s2.0-0034267997
18. Tanaka Y., Eda H., Tanaka T., Udagawa T., Ishikawa T., Horii I., Ishitsuka H., Kataoka T., Taguchi T., Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Research 1990 50 8 2290 2295 2-s2.0-0025263860 (Pubitemid 20134483)
19. Bonaldo P., Sandri M., Cellular and molecular mechanisms of muscle atrophy. Disease Models & Mechanisms 2013 6 1 25 39 2-s2.0-84872094183 10.1242/dmm.010389
20. Scicchitano B. M., Rizzuto E., Musarò A., Counteracting muscle wasting in aging and neuromuscular diseases: the critical role of IGF-1. Aging 2009 1 5 451 457 2-s2.0-77953078946
21. Wang X., Li W., Williams M., Terada N., Alessi D. R., Proud C. G., Regulation of elongation factor 2 kinase by p90 (RSK1) and p70 S6 kinase. The EMBO Journal 2001 20 16 4370 4379 2-s2.0-0035881470 10.1093/emboj/20.16.4370 (Pubitemid 32772031)
22. Pelosi M., Marampon F., Zani B. M., Prudente S., Perlas E., Caputo V., Cianetti L., Berno V., Narumiya S., Kang S. W., Musarò A., Rosenthal N., ROCK2 and its alternatively spliced isoform ROCK2m positively control the maturation of the myogenic program. Molecular and Cellular Biology 2007 27 17 6163 6176 2-s2.0-34548275925 10.1128/MCB.01735-06 (Pubitemid 47326703)
23. Roux P. P., Ballif B. A., Anjum R., Gygi S. P., Blenis J., Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proceedings of the National Academy of Sciences of the United States of America 2004 101 37 13489 13494 2-s2.0-4544384577 10.1073/pnas.0405659101 (Pubitemid 39238430)
24. Lokireddy S., Wijesoma I. W., Bonala S., Wei M., Sze S. K., McFarlane C., Kambadur R., Sharma M., Myostatin is a novel tumoral factor that induces cancer cachexia. The Biochemical Journal 2012 446 1 23 36 2-s2.0-84864762337 10.1042/BJ20112024
25. Bentzinger C. F., Wang Y. X., Dumont N. A., Rudnicki M. A., Cellular dynamics in the muscle satellite cell niche. EMBO Reports 2013 14 12 1062 1072 10.1038/embor.2013.182
26. Mihara M., Hashizume M., Yoshida H., Suzuki M., Shiina M., IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clinical Science 2012 122 4 143 159 2-s2.0-84555205600 10.1042/CS20110340
27. Heinrich P. C., Behrmann I., Haan S., Hermanns H. M., Müller-Newen G., Schaper F., Principles of interleukin (IL)-6-type cytokine signalling and its regulation. The Biochemical Journal 2003 374 1 1 20 2-s2.0-0041677606 10.1042/BJ20030407 (Pubitemid 37046923)
28. Peng X.-D., Xu P.-Z., Chen M.-L., Hahn-Windgassen A., Skeen J., Jacobs J., Sundararajan D., Chen W. S., Crawford S. E., Coleman K. G., Hay N., Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes and Development 2003 17 11 1352 1365 2-s2.0-0038624395 (Pubitemid 36666005)
29. Sandri M., Signaling in muscle atrophy and hypertrophy. Physiology 2008 23 3 160 170 2-s2.0-49049083353 10.1152/physiol.00041.2007
30. Zaki M. H., Nemeth J. A., Trikha M., CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. International Journal of Cancer 2004 111 4 592 595 2-s2.0-3843139682 10.1002/ijc.20270 (Pubitemid 39045327)
31. Deshmane S. L., Kremlev S., Amini S., Sawaya B. E., Monocyte chemoattractant protein-1 (MCP-1): an overview. Journal of Interferon and Cytokine Research 2009 29 6 313 325 2-s2.0-66149172257 10.1089/jir.2008.0027
32. Sell H., Dietze-Schroeder D., Kaiser U., Eckel J., Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. Endocrinology 2006 147 5 2458 2467 2-s2.0-33645888426 10.1210/en.2005-0969
33. Carson J. A., Baltgalvis K. A., Interleukin 6 as a key regulator of muscle mass during cachexia. Exercise and Sport Sciences Reviews 2010 38 4 168 176 2-s2.0-77958010525 10.1097/JES.0b013e3181f44f11